5 results about "Acute inflammatory reaction" patented technology

This invention belongs to the field of cosmetic technology, specifically relating to a composition for skin barrier repair and anti-inflammation after non-surgical cosmetic procedures and its application. The composition comprises Xinjiang comfrey peptide and Xinjiang comfrey naphthoquinone, with a mass ratio of 50-200:1. This composition synergistically inhibits the release of LPS-induced inflammatory factors, alleviating acute inflammatory reactions such as redness and burning after cosmetic procedures, achieving a dual effect of anti-inflammation and repair. The composition significantly reduces postoperative inflammatory redness and improves discomfort symptoms such as dryness and stinging. Through a multi-target mechanism, this invention solves the technical problems of existing repair products having single functions and slow onset of action, providing a highly efficient and comprehensive repair solution for skin after cosmetic procedures.

This invention provides a medicinal ointment for treating rhinitis based on a traditional Chinese medicine compound and its preparation method, relating to the field of traditional Chinese medicine technology. The medicinal ointment for treating rhinitis based on a traditional Chinese medicine compound comprises the following components in parts by weight: Bupleurum chinense 2-10 parts, Dictamnus dasycarpus root bark 3-7 parts, Magnolia biondii flower 8-12 parts, Xanthium sibiricum fruit 4-10 parts, Centipeda minima 2-6 parts, Liquidambar formosana fruit 6-10 parts, Chrysanthemum indicum flower 6-10 parts, Angelica dahurica root 6-12 parts, Houttuynia cordata flower 8-12 parts, Borneol 1-3 parts, Menthol 1-3 parts, Ligusticum chuanxiong rhizome 5-13 parts, Scutellaria baicalensis root 8-12 parts. The ingredients are: 5-11 parts licorice root, 9-10 parts calamus, 1-5 parts Fritillaria thunbergii, 2-6 parts Gleditsia sinensis thorns, 6-10 parts Saposhnikovia divaricata, 8-12 parts Cynanchum paniculatum, 3-9 parts Kochia scoparia, 1-2 parts artificial musk, 5-8 parts ginger, 3-4 parts myrrh, 4-6 parts Schisandra chinensis, 1-3 parts petrolatum, 1-3 parts beeswax, and 2-3 parts coconut oil. In this invention, myrrh reduces acute inflammatory reactions of the nasal mucosa through its anti-inflammatory effect, while Schisandra chinensis reduces secretions through its astringent effect. The combination of the two can effectively relieve nasal congestion and runny nose symptoms.

This invention belongs to the field of cosmetic technology, specifically relating to a composition for skin barrier repair and anti-inflammation after non-surgical cosmetic procedures and its application. The composition comprises Xinjiang comfrey peptide and Xinjiang comfrey naphthoquinone, with a mass ratio of 50-200:1. This composition synergistically inhibits the release of LPS-induced inflammatory factors, alleviating acute inflammatory reactions such as redness and burning after cosmetic procedures, achieving a dual effect of anti-inflammation and repair. The composition significantly reduces postoperative inflammatory redness and improves discomfort symptoms such as dryness and stinging. Through a multi-target mechanism, this invention solves the technical problems of existing repair products having single functions and slow onset of action, providing a highly efficient and comprehensive repair solution for skin after cosmetic procedures.

The invention relates to an application of Kp1 (at) HCeO2 (at) SAM in preparation of drugs for treating or improving inflammatory bowel diseases, and the Kp1 (at) HCeO2 (at) SAM is prepared by embedding KP1-loaded HCeO2 composite nanoparticles into SAM. The invention further provides the Kp1 (at) HCeO2 (at) SAM for treating or improving the inflammatory bowel disease and a preparation method of the Kp1 (at) HCeO2 (at) SAM. According to the invention, the oral KP1 (at) HCeO2 (at) SAM composite microspheres are constructed, so that the acute inflammatory response of IBD is coordinated and intervened, and the chronic fibrosis process is reversed. In a DSS-induced mouse colitis model, the platform shows a staged curative effect: in an acute inflammation stage, HCeO2 efficiently clears active oxygen, promotes macrophage to be converted into M2 anti-inflammatory phenotype and reduces inflammatory factor expression, so that intestinal barrier function recovery is promoted; in the chronic fibrosis period, the sustained-release KP1 oligopeptide can inhibit a TGF-beta / Smad pathway in a targeted mode, myofibroblast activation and collagen deposition are remarkably inhibited, and therefore intestinal fibrosis lesion is reversed. Therefore, the composite microsphere disclosed by the invention, as a novel oral preparation for treating IBD, shows a wide clinical application prospect.

The invention provides a construction method and application of an intermittent force correction mouse model, and the method comprises the following steps: S1, fixing a mouse: fixing the head of the mouse after anesthesia, and exposing an anterior tooth area; s2, tooth separation: separating incisor teeth on two sides; s3, copper wire placement, wherein the pre-bent copper wire with the specific diameter is placed between the incisor teeth on the two sides; s4, shape adjustment: adjusting the position of the copper wire to ensure that the copper wire is located at the incisor gingival papilla, and reserving an incisor end function space; s5, coating a self-acid etching adhesive on the tooth surface; s6, carrying out light curing; s7, fluid resin fixing and shaping, wherein the copper wires are wrapped with the fluid resin through stacking and shaping; s8, photocuring lasts for a certain time, and the incisor teeth of the mouse are expanded to a preset distance; the animal model provided by the invention can not generate serious acute inflammatory reaction and can avoid excessive compression on periodontium, and the intermittent force correction mouse model without inflammatory reaction constructed by the invention can meet specific research and treatment requirements.